<div id="readability-page-1"><div><h2>How United Laboratories International Holdings' Latest Numbers Set the Stage for the Narrative</h2> <p>United Laboratories International Holdings (SEHK:3933) has put up a busy FY 2025 first half, with revenue of about C¥7.5b and basic EPS of C¥1.04 sitting against trailing twelve month revenue of roughly C¥14.1b and basic EPS of C¥1.69. Investors are sifting through what the shift in earnings power really means. Over the last three reported half year periods, revenue has moved from C¥7.2b in 1H 2024 to C¥6.6b in 2H 2024 and then C¥7.5b in 1H 2025, while basic EPS has gone from C¥0.82 to C¥0.64 and then C¥1.04. This sets up a results season where the focus falls squarely on how much of that earnings profile can hold up if margins stay under pressure.</p> <p>See our full analysis for United Laboratories International Holdings.</p><p>With the headline numbers on the table, the next step is to see how this mix of revenue, EPS and margin trends lines up with the big narratives investors already have in mind about United Laboratories International Holdings.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a97bc5e5-972b-4478-b834-7b23e295ac97/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTAzLTI1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a97bc5e5-972b-4478-b834-7b23e295ac97/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTAzLTI1"/><figcaption>SEHK:3933 Revenue &amp; Expenses Breakdown as at Mar 2026</figcaption></figure> <h2>Margins Under Pressure, Even As Profit Holds Up</h2> <ul> <li>Trailing net profit margin moved from 19.3% to 15.8% over the last year, while trailing twelve month net income excluding extra items was C¥3.1b on about C¥14.1b of revenue.</li> <li>What bears focus on is that margin compression and weaker free cash flow coverage of the 6.19% dividend align with a cautious view, yet: <ul> <li>Net income excluding extra items over the last three reported half years was C¥1.5b, C¥1.2b and then C¥1.9b, which sits alongside the 15.8% trailing margin rather than pointing to a collapse in profitability.</li> <li>This challenges a very bearish take that margins are unraveling entirely, while still backing the concern that current dividend payouts will likely stay under scrutiny until cash flows and margins are better aligned.</li> </ul> </li> </ul> <h2>Valuation Gap Versus Peers And DCF Fair Value</h2> <ul> <li>The company trades on a trailing P/E of 8.6x compared with 11.5x for the Hong Kong pharmaceuticals industry and 23.7x for peers, while a DCF fair value of HK$26.03 sits well above the current HK$10.27 share price.</li> <li>Supporters of a bullish view point to this valuation discount and earnings record as a potential upside setup, but the numbers cut both ways: <ul> <li>The gap between HK$10.27 and the HK$26.03 DCF fair value, together with mid double digit annual earnings growth over five years, is often cited in support of the bullish case that the stock is priced below what those models imply.</li> <li>At the same time, revenue growth running at about 5.9% compared with a Hong Kong market average of 8.2% highlights why some investors question how quickly that valuation gap might close, even if the discount looks large on paper.</li> </ul> </li> </ul> <p>Some investors want to see how this valuation picture fits into a wider story of growth, risk and expectations before making their own call, so it can help to step back and see how others are framing the trade through different market narratives. Curious how numbers become stories that shape markets? Explore Community Narratives</p> <h2>Earnings Trend Steadier Than Revenue Growth</h2> <ul> <li>Over the last three half year periods, revenue moved from C¥7.2b to C¥6.6b and then to C¥7.5b, while basic EPS across the same halves came in at C¥0.82, C¥0.64 and then C¥1.04.</li> <li>Supporters of a bullish stance often highlight that pattern as evidence that the business has held its earnings profile even while top line growth trailed the Hong Kong market, which the figures partly support: <ul> <li>Trailing twelve month basic EPS figures of C¥1.46, C¥1.69 and C¥1.11 across the last three LTM snapshots show earnings staying in a relatively tight band, which lines up with the idea that profitability has been more resilient than the slower 5.9% revenue growth might suggest.</li> <li>However, the move in net profit margin from 19.3% to 15.8% means the bullish argument needs to account for earnings quality as well as headline EPS, since it shows more pressure at the bottom line than the stable earnings track alone would suggest.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on United Laboratories International Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>After weighing both the cautious and optimistic angles, the real question is how you see the balance between risk and reward. Move quickly, review the numbers in detail and use the 4 key rewards and 1 important warning sign</p> <h2>See What Else Is Out There</h2> <p>Margin compression from 19.3% to 15.8%, softer free cash flow coverage of the 6.19% dividend, and slower 5.9% revenue growth all point to pressure points investors cannot ignore.</p> <p>If you want income ideas where payouts and fundamentals work harder for you, take a few minutes today to check stocks in the 474 dividend fortresses</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

03933

<p>United Laboratories International Holdings (SEHK:3933) reported a busy FY 2025 first half with revenue of C¥7.5b and basic EPS of C¥1.04, showing a mixed earnings profile amid margin compression. The trailing net profit margin decreased from 19.3% to 15.8%, raising concerns over dividend sustainability. The company trades at a trailing P/E of 8.6x, significantly lower than industry peers, suggesting a valuation gap. While some investors remain bullish due to potential upside, revenue growth of 5.9% lags behind the market average, prompting caution about future performance and dividend payouts.</p>

United Laboratories International Holdings (SEHK:3933) Margin Compression Challenges Bullish Narrative